Companies
Recursion Pharmaceuticals
operates one of the largest robotic phenotypic-screening facilities for lab-in-the-loop data generation (Recursion OS); it combined with Exscientia in November 2024 to form an end-to-end AI discovery company.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | up to 2 million experiments per week | recursion.com · sec.gov |
| Production site | automated laboratories in Salt Lake City, Utah and Milton Park, Oxfordshire | ir.recursion.com · recursion.com · sec.gov |
| Headcount | 550 employees | ir.recursion.com |
| Revenue | $6.5 million for the first quarter of 2026 | sec.gov |
| Regulatory approval | company must comply with comprehensive regulatory requirements to commercialize drug candidates medium confidence | ir.recursion.com · sec.gov |
Independent sources: ir.recursion.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI drug design & AlphaFold applications | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.